News

The NAPOLI-1 Phase III study was conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. The primary log-rank analysis of overall survival was statistically significant

Preclinical data that supported this approval will be presented in a poster session at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO) on 6 May

The option grants the potential commercial partner an exclusive, time-limited right to negotiate, in good faith, the terms of a definitive license agreement with respect to development, distribution

TRV130 is a small molecule G protein biased ligand at the mu opioid receptor. Phase IIa/b study is a multicenter, randomized trial designed to assess the effects of

The Phase I study is Complexa’s first human clinical trial designed to assess the safety and pharmacokinetics of its CXA-10. With the use of various biomarkers, this study

Purixan is a 20mg/ml oral suspension of existing ALL treatment mercaptopurine. Prior to Xaluprine and Purixan, mercaptopurine has only been available as a 50mg tablet for many years.

ADXS-HPV is Advaxis’ lead immunotherapy drug candidate designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for

According to Allergan, the Irish Medicines Board’s positive opinion an important step towards securing national licenses in the 14 European countries involved in the MRP and marks a

Grupo Ferrer Internacional (Ferrer) is commercializing ADASUVE in the Nordic countries via a distribution agreement with Medivir. Ferrer is Alexza’s commercial partner for ADASUVE in the Europe, Latin